The fall of Cassava Sciences’s Alzheimer’s drug, simufilam

On November 25, Cassava Sciences ended a Phase 3 trial of its controversial Alzheimer’s drug, simufilam, following years of scrutiny.

Illustration: Anna Kim, Photos: Adobe Stock By Caroline Catherman December 11, 2024 • 4 min read TOPICS: Pharma / Clinical Trials & Evidence Generation / Clinical Trials An upcoming Alzheimer’s drug that garnered millions in federal funding has officially been put to bed. Biopharmaceutical company Cassava Sciences announced on November 25 that it had discontinued its Phase 3 clinical trial of drug simufilam. The randomized, double-blind trial found no statistically significant change in patient cognition or function—its co-primary endpoints—after 52 weeks when comparing a 403-person experiment

related reading

• The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
• Contrary Research on X: "The Virtual Cell Revolution" / Xx.com
• Nintil - The failure of monoclonal antibody therapy for Alzheimer's Disease, implications for the Amyloid Cascade Hypothesisnintil.com
• It’s just a first step, but this new Alzheimer’s drug could be a huge breakthrough | Jonathan Schott | The Guardiantheguardian.com
• The amyloid hypothesis in Alzheimer disease: new insights from new therapeuticsnature.com
• About Us – Hindenburg Researchhindenburgresearch.com
• Clinic-in-the-Loopasimov.press
• Learning Well from Being Wrongnivedithasi.github.io
• Where are all the trillion dollar biotechs?ladanuzhna.xyz
• “Real world” eligibility for aducanumab: A Podcast with Tim Anderson and Marco Canevelligeripal.org
• Nature's drug database - The Works in Progress Newsletterworksinprogress.news
• Eroom's law - Wikipediaen.wikipedia.org